[Intravenous loading with galactose as a liver function test. Methods and clinical value].

H D Kuntz; E Kuntz

Home/Archive/PubMed

PubMed · 6873856

[Intravenous loading with galactose as a liver function test. Methods and clinical value].

H D Kuntz·E Kuntz

View original source ↗Export metadata ↓

Abstract

The determination of the galactose elimination capacity with the method according to Tygstrup (1966) is the only test which detects the "functional hepatocyte mass" and thus constitutes a quantitative test for the metabolic function of the liver. In this determination of the maximum hepatic elimination capacity, differences with bilirubin, hemolysis and hyperlipidemia do not occur; reliable results are also obtained in disorders of hepatic secretion. Side-effects from the test substance galactose are not to be expected. It is also possible to determine galactose without difficulty in capillary blood. The i.v. galactose test permits an estimation of the degree of severity of liver diseases and can also be recommended for routine use in the investigation of specific hepatological questions.

Explore related subjects

Galactose Galactose Dehydrogenases Humans Injections, Intravenous Liver Liver Diseases Liver Function Tests English Abstract Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

H D Kuntz, E Kuntz. 1983-06-02. [Intravenous loading with galactose as a liver function test. Methods and clinical value].. https://pubmed.ncbi.nlm.nih.gov/6873856/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2006

Characterization of an exo-beta-1,3-D-galactanase from Streptomyces avermitilis NBRC14893 acting on arabinogalactan-proteins.

A gene belonging to glycoside hydrolase family 43 (GH43) was isolated from Streptomyces avermitilis NBRC14893. The gene encodes a modular protein consisting of N-terminal GH43 module and a family 13 carbohydrate-binding module at the C-terminus. The gene corresponding to the GH43 module was expressed in Escherichia coli, and the gene product was characterized. The recombinant enzyme specifically hydrolyzed only beta-1,3-linkage of two D-galactosyl residues at non-reducing ends of the substrates. The analysis of the hydrolysis products indicated that the enzyme produced galactose from beta-1,3-D-galactan in an exo-acting manner. When the enzyme catalyze hydrolysis of the arabinogalactan-protein, the enzyme produced oligosaccharides together with galactose, suggesting that the enzyme is able to accommodate beta-1,6-linked D-galactosyl side chains. These properties are the same as the other previously reported exo-beta-1,3-D-galactanases. Therefore, we concluded the isolated gene certainly encodes an exo-beta-1,3-D-galactanase. This is the first report of exo-beta-1,3-D-galactanase from actinomycetes.

Galactose↗

PubMed2006

Enzymatic synthesis of aldonic acids.

Several aldonic acids (D-mannonic, D-galactonic, D-xylonic, 2-deoxy-D-arabinohexonic (2-deoxy-D-gluconic)) were prepared on a scale of several grams by a simple oxidation catalyzed by glucose oxidase in pure water.

Galactose↗

PubMed2006

Metabolic engineering of Agrobacterium sp. for UDP-galactose regeneration and oligosaccharide synthesis.

Curdlan-producing Agrobacterium sp. is unique in possessing a highly efficient UDP-glucose regeneration system. A broad-host-range expression strategy was successfully developed to exploit the unique metabolic capability for UDP-galactose regeneration during oligosaccharide synthesis. The engineered Agrobacterium cells functioned as a UDP-galactose regeneration system, allowing galactose-containing disaccharides to be synthesized from glucose or other simple sugars. Unexpectedly, a lag period of 24h preceded the active synthesis, which could be eliminated with rifampicin. An intracellular nucleotide profiling revealed that the UMP level was elevated by 3.8 fold in the presence of rifampicin, suggesting that rifampicin simulated a nitrogen-limitation condition that triggered the metabolic change. Product selectivity was improved nearly 40-fold by using high acceptor concentration and restricting glucose supply. N-acetyllactosamine concentration near 20 mM (7.5 g/l) was obtained, demonstrating the effectiveness of the engineered strain in UDP-galactose regeneration. This organism could be engineered to regenerate other UDP-sugar nucleotides using the same strategy as illustrated here.

Galactose↗